Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses.

Xiaowen ShiBin ZhangZhenliang ChuBingjiang HanXueping ZhangPing HuangJibo Han

Published in: Cardiovascular therapeutics (2021)

Our results provide further evidence for the potential use of Wog as an antioxidative agent for treatment of cardiac hypertrophy, and Nrf-2 might serve as a therapeutic target in the treatment of cardiac hypertrophy.

Keyphrases

oxidative stress
anti inflammatory
combination therapy